Schuster, Herbert <br/><br/>
Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.  [electronic resource] 

 -  Atherosclerosis  Mar 2008 
 - 355-62 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-1484 
<br/><br/><label>Standard No.: </label>10.1016/j.atherosclerosis.2007.05.029  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Alkanesulfonates--administration & dosage<br/>Apolipoprotein A-I--blood<br/>Apolipoprotein C-III--blood<br/>Apolipoproteins--blood<br/>Apolipoproteins B--blood<br/>Cholesterol, LDL--blood<br/>Dose-Response Relationship, Drug<br/>Dyslipidemias--drug therapy<br/>Female<br/>Humans<br/>Insulin Resistance<br/>Male<br/>Middle Aged<br/>PPAR alpha--agonists<br/>PPAR gamma--agonists<br/>Phenylpropionates--administration & dosage